Drug Profile
Research programme: antisense DNA therapeutics - Oncotelic Therapeutics
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Oncotelic
- Developer Oncotelic Therapeutics
- Class Antisense DNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified